Ifosfamide and Hearing loss - a phase IV clinical study of FDA data

Summary:

Hearing loss is reported as a side effect among people who take Ifosfamide (ifosfamide), especially for people who are female, 10-19 old, also take Methotrexate, and have Osteosarcoma.

The phase IV clinical study analyzes which people have Hearing loss when taking Ifosfamide. It is created by eHealthMe based on reports of 21,274 people who have side effects when taking Ifosfamide from the FDA, and is updated regularly.

What is Ifosfamide?

Ifosfamide has active ingredients of ifosfamide. eHealthMe is studying from 21,285 Ifosfamide users. Check the latest studies of Ifosfamide.

What is Hearing loss?

Hearing loss is found to be associated with 1,359 drugs and 2,384 conditions by eHealthMe. Check the latest studies of Hearing loss.

On Aug, 04, 2026

21,274 people reported to have side effects when taking Ifosfamide.
Among them, 95 people (0.45%) have Hearing loss.

Among these 95 people:

What is the gender of people who have Hearing loss when taking Ifosfamide? *

female: 52.17 %
male: 47.83 %

What is the age of people who have Hearing loss when taking Ifosfamide? *

What are other drugs people take besides Ifosfamide? *

What are other side effects people have besides Hearing loss? *

Thrombocytopenia (decrease of platelets in blood): 19 people, 20.00%
Anaemia (lack of blood): 17 people, 17.89%
Renal Impairment (severely reduced kidney function): 14 people, 14.74%
Febrile Neutropenia (fever with reduced white blood cells): 14 people, 14.74%
Nausea And Vomiting: 14 people, 14.74%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 9 people, 9.47%
Nausea (feeling of having an urge to vomit): 8 people, 8.42%
Hepatic Enzyme Increased: 8 people, 8.42%
Diarrhea: 7 people, 7.37%
Blood Creatinine Increased: 7 people, 7.37%

What are the existing conditions these people have? *

Osteosarcoma (a cancerous (malignant) bone tumour): 18 people, 18.95%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 8 people, 8.42%
Medulloblastoma (a fast-growing, high-grade tumour that always begins in the cerebellum): 5 people, 5.26%
Metastases To Lung (cancer spreads to lung): 4 people, 4.21%
Yolk Sac Tumor Site Unspecified: 4 people, 4.21%
Aicardi's Syndrome (aicardi syndrome is a rare genetic malformation syndrome characterized by the partial or complete absence of a key structure in the brain called the corpus callosum): 3 people, 3.16%
Bone Sarcoma (bone cancer): 3 people, 3.16%
Lymphoma (cancer that begins in immune system cells): 2 people, 2.11%
Hodgkin's Lymphoma (cancer originating from white blood cells): 2 people, 2.11%
Metastasis (spreadable cancer to other organ from origin): 2 people, 2.11%

* Approximation only. Some reports may have incomplete information.

Do you take Ifosfamide and have Hearing loss?

- Check whether Hearing loss is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ifosfamide:

Ifosfamide (21,285 reports)

Hearing loss treatments and more:

Hearing loss (30,352 reports)

Browse all side effects of Ifosfamide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hearing loss:

Hearing loss (1,359 drugs)

Browse all the conditions that are associated with Hearing loss:

Hearing loss (2,384 conditions)

Related publications that referenced our studies

Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .
Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on ifosfamide (the active ingredients of Ifosfamide) and Ifosfamide (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.